If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient to patient, a discovery that adds to a growing base of knowledge important for developing more effective precision therapies.
Findings from the study, led by Han Liang, Ph.D., associate professor of Bioinformatics and Computational Biology, and Gordon Mills, M.D., Ph.D., chair of Systems Biology, were published in the April 26 online issue of Cancer Cell.
Liang’s and Mills’ team discovered how a particular type of RNA editing called adenosine to inosine (A-to-I) RNA plays a key role in protein variation in cancer cells. RNA editing is the process by which genetic information is altered in the RNA molecule. Once thought rare in humans and other vertebrates, RNA editing is now recognized as widespread in the human genome.
Since cancer can arise from vastly different protein types and mutations, the promise of individualizing therapies for each patient is reliant upon a better understanding of the protein “genome,” an area of study called proteomics. Understanding the molecular mechanism contributing to protein variation and diversity is a key question in cancer research today, with significant clinical applications for cancer treatment.
“Using data from The Cancer Genome Atlas and the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium, our study provides large-scale direct evidence that A-to-I RNA editing is a source of proteomic diversity in cancer cells,” said Liang. “RNA editing represents a new paradigm for understanding the molecular basis of cancer and developing strategies for precision cancer medicine. If a protein is only highly edited in tumor proteins, but not in normal proteins, then it’s possible that a specific drug could be designed to inhibit the edited mutant protein.”
It has long been known that A-to-I RNA editing allows cells to tweak the RNA molecule resulting in nucleotide sequences which alter DNA “instructions” for how proteins are generated and how they are assembled within the cell.
The researchers demonstrated how A-to-I RNA editing contributes to protein diversity in breast cancer by making changes in amino acid sequences. They found one protein, known as coatomer subunit alpha (COPA), increased cancer cell proliferation, migration and invasion in vitro, following A-to-I RNA editing.
“Collectively, our study suggests that A-to-I RNA editing contributes to protein diversity at least in some cancers,” said Mills. “It is an area of study that deserves more effort from the cancer research community to elucidate the molecular basis of cancers, and potentially developing prognostic and therapeutic approaches.”
The Latest on: Precision cancer medicine
via Google News
The Latest on: Precision cancer medicine
- Syapse Unveils Two New Studies on Use of Machine Learning on Real-World Data to Identify and Treat Cancer With Precision at ASCO 2022on May 27, 2022 at 7:02 am
Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today announced two new studies focused on how the use ...
- Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022on May 26, 2022 at 3:30 pm
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, ...
- Study brings precision medicine closer to reality for diffuse large B cell lymphomaon May 25, 2022 at 5:04 pm
DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets.
- California Bill to Improve Precision Cancer Care Access for Medi-Cal Patients Sails Through Senateon May 25, 2022 at 2:28 pm
The bill, which is headed to the Assembly, will improve access to NCI-designated cancer centers, where patients can receive precision medicine and other advanced care.
- Breast Cancer Society of Canada Grants $350,000 To Precision Oncology Researchon May 25, 2022 at 6:49 am
Breast Cancer Research Call for Proposals Grant Recipient Mousumi Majumder Grant Recipient Mousumi Majumder in a research lab. SARNIA, Ontario, May 25, 2022 (GLOBE NEWSWIRE) -- The Breast Cancer ...
- As Number of Targeted Therapies Increases, Challenges With Precision Medicine Are Not Going Awayon May 24, 2022 at 10:36 am
There are an increasing number of targeted therapies in oncology, but challenges around biomarker testing and treatment selection remain.
- Cancer treatment centers to use precise, pricey proton therapyon May 17, 2022 at 3:00 am
None of the 36 U.S. sites today are in Wisconsin. UW Health and Froedtert Health this week said they plan to launch them by 2024.
- Precision oncology helps prostate cancer patientson May 12, 2022 at 7:27 am
"One in five patients with brain metastatic prostate cancer could therefore benefit from therapy with these targeted drugs," says Mark A. Rubin. Prime example of precision oncology At the same ...
- Prostate cancer patients benefit from precision oncologyon May 10, 2022 at 5:00 pm
Dangerous are advanced stages in which cancer cells have spread to other ... Research and president of the Bern Center for Precision Medicine at the University of Bern and University Hospital ...
via Bing News